Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

Summary

A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.

Conditions

• Blood Disease
• Blood Transfusion, Autologous
• Blood Doping
• Blood Transfusion, Homologous

Interventions

BIOLOGICAL

Homologous Blood Transfusion

Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.

BIOLOGICAL

Autologous Blood Transfusion

Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.

Sponsors & Collaborators

• World Anti-Doping Agency

  collaborator OTHER

• Anti-Doping Lab Qatar

  collaborator UNKNOWN

• Sidra Medicine

  collaborator OTHER

• Laboratorio Antidoping FMSI

  collaborator UNKNOWN

• Hamad Medical Corporation

  lead INDUSTRY

Principal Investigators

• Sven Voss · ADLQ

• Mohamed Yassin · Hamad Medical Corporation

• Francesco Donati · Laboratorio Antidoping FMSI, Rome, Italy

• Costas Georgakopoulos · ADLQ

• Mohammed Alsayrafi · ADLQ

• Jean-Charles Grivel · Sidra Medicine

• Christophe Raynaud · Sidra Medicine

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2018-09-20

Primary Completion

2021-12-31

Completion

2021-12-31

Countries

• Qatar

Study Locations